Kintara Therapeutics Inc (KTRA)

[undtrdr]

Found this succinct summary of the company's current endeavors and pipeline posted on the Yahoo newsfeed ..good read for newbies
Del Mar Pharmaceuticals Inc. (OTCMKTS:DMPI)

DelMar is developing VAL-083. In DNA, sometimes we get what are called interstrand crosslinks, which connect the two strands in DNA and inhibit the standard DNA functions of replication and transcription. Crosslinks are very toxic to surrounding cells, and can quickly induce cell death. VAL-083 seeks to induce interstrand crosslinks in the DNA of cancerous cells, and in turn, induce apoptosis and the halting of cancerous cell replication. This type of crosslink induction is at the core of the majority of cancer therapies - primarily chemotherapy drugs - but DelMar's candidate is a different kind of agent that would allow it to be administered as a single therapy or in combination with some of the most commonly used therapies available - platinum based, or tyrosine kinase based treatments, for example.

The drug is already approved in an oncology indication in China, which sets it in great stead for a US or European approval, and to date we've seen some promising trial results. Mid stage data from an ongoing phase I/II in glioblastoma multiforme brain cancer demonstrated tolerability, low negative side effects, and an improved survival rate at 6, 9 and 12 months following treatment, building on earlier preclinical data that served as proof of concept. GBM is notoriously difficult to treat, and if approved, VAL-083 would be targeting a billion dollar market.

Full completion is expected at the beginning of December this year, and we should get top-line data shortly after. If we get tumor response that mimics mid stage data, the drug could move into a pivotal trial shortly after, and DelMar could be well on its way towards its first approval.
http://finance.yahoo.com/news/4-stocks-consider-biotech-turnaround-165500882.html